By
AVESTHAGEN LIMITED’s Intellectual Property For Diabetes Management Valued at $470 million
AVESTHAGEN LIMITED’s Intellectual Property For Diabetes Management Valued at $470 million .. View More
Byadmin
Avesthagen IP for diabetes management valued at $470 mn
Avesthagen IP for diabetes management valued at $470 mn .. View More
Byadmin
Dr. Villoo Morawala-Patell – Success Story
Dr. Villoo Morawala-Patell – Success Story.. View More
Byadmin
AVESTHAGEN’s first biosimilar molecule AVDESP™ completes Clinical Batch Manufacturing in Malaysia, to move to Clinical Trials
AVESTHAGEN’s first biosimilar molecule AVDESP™ completes Clinical Batch Manufacturing in Malaysia, to move to Clinical Trials.. View More
Byadmin
